Deep Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deep Shah has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Brian Soper
In vivo Services, The Jackson Laboratory, Sacramento, CA, United States
1 shared publicationLindsay Shopland
In vivo Services, The Jackson Laboratory, Sacramento, CA, United States
1 shared publication
Latest Publications
- Open Access
- 25 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1190379
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.
- 25 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1190379
Open AccessCytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.